DGAP-News: CureVac / Key word(s): Research Update/Study results
CureVac Publishes Detailed Interim Phase 1 Data of its COVID-19 Vaccine Candidate, CVnCoV
- Data publication follows positive topline data reported November 2, 2020
- Full pre-print manuscript available on medRxiv
- Company to host conference call and webcast today at 5 p.m. CET (11 a.m. EST)
The previously announced interim data showed that CVnCoV was generally well tolerated across all tested doses (2-12µg) and induced strong binding and neutralizing antibody responses in addition to first indication of T cell activation. The quality of immune response was found to be comparable to recovered COVID-19 patients, closely mimicking the immune response after natural COVID-19 infection.
CureVac will host a conference call and webcast today at 5 p.m. CET (11 a.m. EST) to provide more insight on the detailed Phase 1 interim trial data. The live webcast link and corresponding presentation slides can be accessed via the Investor Relations section of the CureVac homepage at https://www.curevac.com/en/newsroom/events/
CureVac Media Contact
CureVac Investor Relations Contact
For further information, please reference the company's reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at www.sec.gov.
10.11.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.